Treatment options for vWD include desmopressin (1-8-deamino-D-arginine vasopressin, DDAVP), a synthetic analog of vasopressin, to increase plasma factor VIII and vWF levels transiently in patients with vWD and in non-affected individuals with a bleeding disorder. The gene discussed is VWF; the disease is von Willebrand disease (hereditary or acquired).